Novartis (NVS) Q3 2026 (Tue Oct 27 premarket) — net sales <meta name="viewport" content="width=device-width, initial-scale=1.0" />4.52B (+4% USD/cc) tops ~<meta name="viewport" content="width=device-width, initial-scale=1.0" />4.3B est; core EPS $2.46 (+9% USD, +8% cc) beats ~$2.28 est; core operating income $6.04B (+11% USD, +10% cc), core margin 41.6% (+230bp cc); GAAP net income <meta name="viewport" content="width=device-width, initial-scale=1.0" />.20B (-70% USD) hit by <meta name="viewport" content="width=device-width, initial-scale=1.0" />.9B del-desiran IPR&D impairment; Kisqali <meta name="viewport" content="width=device-width, initial-scale=1.0" />.82B (+37% cc) continues to lead growth, Scemblix $593M (+66% cc), Leqvio $506M (+63% cc), Cosentyx <meta name="viewport" content="width=device-width, initial-scale=1.0" />.86B (+9% cc), Entresto <meta name="viewport" content="width=device-width, initial-scale=1.0" />.17B (-38% cc on US generic entry); Q3 FCF $5.1B (-18%); 9M net sales $42.0B (flat cc); FY26 core operating income guide RAISED to 'in line to grow low single digits cc' (from 'low single-digit decline'); Pluvicto earlier-line prostate cancer approvals; remibrutinib positive Phase III in MS

4.52B (+4% USD/cc) tops ~4.3B est; core EPS $2.46 (+9% USD, +8% cc) beats ~$2.28 est; core operating income $6.04B (+11% USD, +10% cc), core margin 41.6% (+230bp cc); GAAP net income .20B (-70% USD) hit by .9B del-desiran IPR&D impairment; Kisqali .82B (+37% cc) continues to lead growth, Scemblix $593M (+66% cc), Leqvio $506M (+63% cc), Cosentyx .86B (+9% cc), Entresto .17B (-38% cc on US generic entry); Q3 FCF $5.1B (-18%); 9M net sales $42.0B (flat cc); FY26 core operating income guide RAISED to 'in line to grow low single digits cc' (from 'low single-digit decline'); Pluvicto earlier-line prostate cancer approvals; remibrutinib positive Phase III in MS" /> 4.52B (+4% USD/cc) tops ~4.3B est; core EPS $2.46 (+9% USD, +8% cc) beats ~$2.28 est; core operating income $6.04B (+11% USD, +10% cc), core margin 41.6% (+230bp cc); GAAP net income .20B (-70% USD) hit by .9B del-desiran IPR&D impairment; Kisqali .82B (+37% cc) continues to lead growth, Scemblix $593M (+66% cc), Leqvio $506M (+63% cc), Cosentyx .86B (+9% cc), Entresto .17B (-38% cc on US generic entry); Q3 FCF $5.1B (-18%); 9M net sales $42.0B (flat cc); FY26 core operating income guide RAISED to 'in line to grow low single digits cc' (from 'low single-digit decline'); Pluvicto earlier-line prostate cancer approvals; remibrutinib positive Phase III in MS" />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.